{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:44:35Z","timestamp":1777866275011,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001409","name":"India Ministry of Science &amp; Technology Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["DST\/20\/015"],"award-info":[{"award-number":["DST\/20\/015"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/IC-06\/003\/91"],"award-info":[{"award-number":["BT\/IC-06\/003\/91"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/NBM0368\/NBM\/09\/20"],"award-info":[{"award-number":["BT\/NBM0368\/NBM\/09\/20"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["DBT\/23\/027"],"award-info":[{"award-number":["DBT\/23\/027"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011753","name":"National Institute of Immunology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011753","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.vaccine.2025.126993","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T05:39:16Z","timestamp":1742189956000},"page":"126993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy"],"prefix":"10.1016","volume":"54","author":[{"given":"Sadaf","family":"Parveen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pragyan Parimita","family":"Rath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shams","family":"Tabrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Summaiya","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaikh Zikra","family":"Arkam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheenam","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahnawaz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susheel K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iqbal Taliy","family":"Junaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhiraj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Theisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asif","family":"Mohmmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinakar M.","family":"Salunke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agam P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawan","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.126993_bb0005","series-title":"World malaria report 2022","author":"World Health Organization","year":"2022"},{"issue":"8","key":"10.1016\/j.vaccine.2025.126993_bb0010","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1172\/JCI21682","article-title":"Antimalarial drug resistance","volume":"113","author":"White","year":"2004","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.vaccine.2025.126993_bb0015","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41590-018-0228-6","article-title":"Malaria prevention: from immunological concepts to effective vaccines and protective antibodies","volume":"19","author":"Cockburn","year":"2018","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126993_bb0020","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","article-title":"RTS,S\/AS01 vaccine (Mosquirix\u2122): an overview","volume":"16","author":"Laurens","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"10287","key":"10.1016\/j.vaccine.2025.126993_bb0025","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.126993_bb0030","series-title":"World malaria report 2015","author":"World Health Organization","year":"2015"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126993_bb0035","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial","volume":"22","author":"Datoo","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126993_bb0040","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41591-023-02745-2","article-title":"Integrating vaccines and monoclonal antibodies into malaria prevention","volume":"30","author":"Taylor","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126993_bb0045","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.4512","article-title":"A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite","volume":"24","author":"Kisalu","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126993_bb0050","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.immuni.2020.08.014","article-title":"A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver","volume":"53","author":"Wang","year":"2020","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126993_bb0055","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.143958","article-title":"Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention","volume":"6","author":"Kisalu","year":"2021","journal-title":"JCI Insight"},{"issue":"20","key":"10.1016\/j.vaccine.2025.126993_bb0060","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1056\/NEJMoa2206966","article-title":"Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali","volume":"387","author":"Kayentao","year":"2022","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.vaccine.2025.126993_bb0065","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1056\/NEJMoa2312775","article-title":"Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria","volume":"390","author":"Kayentao","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126993_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J Biomed Sci"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126993_bb0075","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jmb.2005.01.053","article-title":"Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability","volume":"347","author":"R\u00f6thlisberger","year":"2005","journal-title":"J Mol Biol"},{"issue":"7121","key":"10.1016\/j.vaccine.2025.126993_bb0080","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nature05361","article-title":"The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites","volume":"444","author":"Kumar","year":"2006","journal-title":"Nature"},{"issue":"4706","key":"10.1016\/j.vaccine.2025.126993_bb0085","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1126\/science.2409595","article-title":"Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria","volume":"228","author":"Zavala","year":"1985","journal-title":"Science"},{"issue":"6614","key":"10.1016\/j.vaccine.2025.126993_bb0090","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/385336a0","article-title":"Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes","volume":"385","author":"M\u00e9nard","year":"1997","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.vaccine.2025.126993_bb0095","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/emboj\/21.7.1586","article-title":"Levels of circumsporozoite protein in the Plasmodium oocyst determine sporozoite morphology","volume":"21","author":"Thathy","year":"2002","journal-title":"EMBO J"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126993_bb0100","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1084\/jem.20101488","article-title":"The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host","volume":"208","author":"Coppi","year":"2011","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126993_bb0105","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.cell.2007.09.013","article-title":"Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite","volume":"131","author":"Singh","year":"2007","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126993_bb0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1084\/jem.20040989","article-title":"The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion","volume":"201","author":"Coppi","year":"2005","journal-title":"J Exp Med"},{"issue":"4662","key":"10.1016\/j.vaccine.2025.126993_bb0115","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1126\/science.6204383","article-title":"Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum","volume":"225","author":"Dame","year":"1984","journal-title":"Science"},{"issue":"39","key":"10.1016\/j.vaccine.2025.126993_bb0120","doi-asserted-by":"crossref","first-page":"26951","DOI":"10.1074\/jbc.M109.013706","article-title":"Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate","volume":"284","author":"Plassmeyer","year":"2009","journal-title":"J Biol Chem"},{"issue":"49","key":"10.1016\/j.vaccine.2025.126993_bb0125","doi-asserted-by":"crossref","first-page":"47613","DOI":"10.1074\/jbc.M208453200","article-title":"Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity","volume":"277","author":"Tewari","year":"2002","journal-title":"J Biol Chem"},{"issue":"34","key":"10.1016\/j.vaccine.2025.126993_bb0130","doi-asserted-by":"crossref","first-page":"12528","DOI":"10.1073\/pnas.1407362111","article-title":"Vectored antibody gene delivery protects against Plasmodium falciparum sporozoite challenge in mice","volume":"111","author":"Deal","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126993_bb0135","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1074\/jbc.RA119.011268","article-title":"The Plasmodium falciparum circumsporozoite protein produced in Lactococcus lactis is pure and stable","volume":"295","author":"Singh","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2025.126993_bb0140","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.molimm.2019.07.010","article-title":"Cross-clade antibody reactivity may attenuate the ability of influenza virus to evade the immune response","volume":"114","author":"Vashisht","year":"2019","journal-title":"Mol Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126993_bb0145","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nprot.2010.5","article-title":"I-TASSER: a unified platform for automated protein structure and function prediction","volume":"5","author":"Roy","year":"2010","journal-title":"Nat Protoc"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126993_bb0150","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/prot.21117","article-title":"PIPER: an FFT-based protein docking program with pairwise potentials","volume":"65","author":"Kozakov","year":"2006","journal-title":"Proteins"},{"key":"10.1016\/j.vaccine.2025.126993_bb0155","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-1-4939-6798-8_14","article-title":"Investigating Protein-Peptide Interactions Using the Schr\u00f6dinger Computational Suite","volume":"1561","author":"Bhachoo","year":"2017","journal-title":"Methods Mol Biol"},{"issue":"20","key":"10.1016\/j.vaccine.2025.126993_bb0160","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1093\/bioinformatics\/bts493","article-title":"Application of asymmetric statistical potentials to antibody-protein docking","volume":"28","author":"Brenke","year":"2012","journal-title":"Bioinformatics"},{"issue":"23","key":"10.1016\/j.vaccine.2025.126993_bb0165","doi-asserted-by":"crossref","first-page":"14016","DOI":"10.1080\/07391102.2023.2176361","article-title":"Designing of new tetrahydro-\u03b2-carboline-based ABCG2 inhibitors using 3D-QSAR, molecular docking, and DFT tools","volume":"41","author":"Ahmad","year":"2023","journal-title":"J Biomol Struct Dyn"},{"issue":"26","key":"10.1016\/j.vaccine.2025.126993_bb0170","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","article-title":"Seven-Year Efficacy of RTS,S\/AS01 Malaria Vaccine among Young African Children","volume":"374","author":"Olotu","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126993_bb0175","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/cid\/ciu954","article-title":"Vaccines against malaria","volume":"60","author":"Ouattara","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126993_bb0180","series-title":"World malaria report 2015","author":"World Health Organization","year":"2015"},{"issue":"9","key":"10.1016\/j.vaccine.2025.126993_bb0185","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa2034031","article-title":"A Monoclonal Antibody for Malaria Prevention","volume":"385","author":"Gaudinski","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126993_bb0190","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1128\/IAI.01249-13","article-title":"Model for in vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum","volume":"82","author":"Sack","year":"2014","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126993_bb0195","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMoa2203067","article-title":"Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria","volume":"387","author":"Wu","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2025.126993_bb0200","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.3389\/fimmu.2020.01986","article-title":"Phage Display Derived Monoclonal Antibodies: From Bench to Bedside","volume":"28","author":"Alfaleh","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126993_bb0205","article-title":"Antibodies to watch in 2020","volume":"Jan-Dec;12(1):1703531","author":"Kaplon","year":"2020","journal-title":"MAbs"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126993_bb0210","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41577-019-0209-5","article-title":"Antibodies against Plasmodium falciparum malaria at the molecular level","volume":"19","author":"Julien","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126993_bb0215","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1476-5381.2010.00936.x","article-title":"Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action","volume":"161","author":"Vauquelin","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126993_bb0220","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1517\/17460441003677725","article-title":"The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety","volume":"5","author":"Copeland","year":"2010","journal-title":"Expert Opin Drug Discov"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126993_bb0225","doi-asserted-by":"crossref","first-page":"37457","DOI":"10.1038\/srep37457","article-title":"Antibody-antigen kinetics constrain intracellular humoral immunity","volume":"24","author":"Bottermann","year":"2016","journal-title":"Sci Rep"},{"issue":"43","key":"10.1016\/j.vaccine.2025.126993_bb0230","doi-asserted-by":"crossref","first-page":"13225","DOI":"10.1073\/pnas.1518361112","article-title":"Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration","volume":"112","author":"Lee","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126993_bb0235","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ab.2013.07.025","article-title":"Off-rate screening for selection of high-affinity anti-drug antibodies","volume":"441","author":"Ylera","year":"2013","journal-title":"Anal Biochem"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126993_bb0240","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1021\/acs.analchem.7b01221","article-title":"Comparison of Three Antihapten VHH Selection Strategies for the Development of Highly Sensitive Immunoassays for Microcystins","volume":"89","author":"P\u00edrez-Schirmer","year":"2017","journal-title":"Anal Chem"},{"issue":"7","key":"10.1016\/j.vaccine.2025.126993_bb0245","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1021\/jm5003815","article-title":"Efficient hit and lead compound evaluation strategy based on off-rate screening by surface plasmon resonance","volume":"57","author":"Liu","year":"2014","journal-title":"J Med Chem"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25002907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25002907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:21:31Z","timestamp":1777537291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25002907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":49,"alternative-id":["S0264410X25002907"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126993","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126993","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126993"}}